In a phase II study, researchers evaluated the efficacy of ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab—a chemoimmunotherapy and targeted therapy combination—in 45 previously untreated patients with IGHV-mutated chronic lymphocytic leukemia (CLL). Nitin Jain, MD, of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, and colleagues reported the long-term outcomes of the study (after a median follow-up of 56.8 months) at the European Hematology Association (EHA) 2022 Congress (Abstract S149).
Nitin Jain, MD
After just three cycles, 87% of patients had undetectable measurable residual disease, with improved responses after continued therapy. The 5-year progression-free survival and overall survival rates were 97.7% and 97.8%, respectively. One patient had CLL progression, and no patients had Richter’s transformation.
The findings reveal that ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab offers high rates of undetectable measurable residual disease remission and long-term survival with only three cycles of chemotherapy, as opposed to previous treatments with six cycles of chemotherapy.
Disclosure: For full disclosures of the study authors, visit library.ehaweb.org.
